IsoRay (ISR) Brain Cancer Results 'Impressive' - Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IsoRay (ISR) Reports 'Striking' Results from Study of Brain Cancer Patients Treated with Cesium-131
December 1, 2014 8:27 AM ESTIsoRay Inc. (NYSE: ISR) today announced the striking results of a study of brain cancer patients treated with IsoRays Cesium-131 internal radiation (brachytherapy) cancer therapy. The findings of the study, conducted by researchers at Barrow Neurological Institute, were presented at the November 2014 annual meeting of the Society for Neuro-Oncology in Miami, Florida.
The Barrow study reported on 27 patients who had a variety of deadly brain cancers, including high grade gliomas, high grade meningiomas, and brain metastases. The patients had received an average of 2 and as many as 4 extensive earlier treatments that... More
